Stockholm, Sweden, June 9, 2021 – Oasmia Pharmaceutical AB, an innovation-focused specialty pharmaceutical company, today provides an update on research and development efforts on its proprietary technology platform, XR-17™.
In addition to building a strong clinical product pipeline in cancer indications, Oasmia is committed to enhancing XR-17 which can be applied to medicines used in many therapeutic areas.
Recent progress in research aiming to enhance the XR-17 drug delivery platform has been made as follows:
XR-18 – Enhancement of the XR-17 platform: XR-18 is a research and development effort based on the XR-17 technology platform intended to provide enhanced properties that improve clinical formulations and applications of active pharmaceutical ingredients (APIs) for cancer treatment. This effort has recently generated promising data including:
- Addition of components to existing XR-17 formulation improving certain properties.
- Synthesis of novel excipients exhibiting XR-17-like properties with enhanced stability characteristics. These modifications will be evaluated for feasibility in various drug formulations.
XR-19 – Encapsulation of multiple APIs: XR-19 is an enhancement of existing XR-17 features with new functionalities, specifically the encapsulation of multiple APIs in one micellar envelope. Recent proof-of-concept studies have shown novel capabilities of the XR-17 platform, demonstrating its potential for dual encapsulation of APIs. Subsequent research demonstrated the molecular makeup of the encapsulation, providing the basis for future development. The Company will move forward and explore applications in cancer and other indications.
The company is pursuing intellectual property enhancements for these opportunities.
Dr. Reinhard Koenig, Oasmia’s Chief Scientific Officer added, “Oasmia has a growing pipeline of oncology programmes in clinical development. Internal research intended to expand applications of Oasmia’s XR-17 technology platform is ongoing and showing progress. Depending on our ongoing research, we hope to add more options to our future oncology portfolio. We look forward to progressing the research programme and to reporting progress in the future.”
For More Information:
Oasmia Pharmaceutical AB
Francois Martelet, Chief Executive Officer
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
Consilium Strategic Communications (For Oasmia)
Jonathan Birt, Chris Welsh, Ashley Tapp
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com
About Oasmia Pharmaceutical AB
Oasmia is a specialty pharmaceutical company focused on the development of new therapeutic options for patients suffering from hard-to-treat cancers. It has a growing pipeline of clinical-stage assets targeting late-stage cancers. Oasmia’s most advanced program is Apealea® (paclitaxel micellar), which is being made available to ovarian cancer patients through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, in clinical development for late-stage ovarian cancer, and docetaxel micellar, in development for advanced prostate cancer. Oasmia’s proprietary drug delivery platform XR-17™ is designed to improve drug solubility, efficacy and safety. Oasmia’s shares are traded on Nasdaq Stockholm (OASM). To find out more about Oasmia please visit www.vivesto.com.